EUVIMEDEUVIMED entdecken
Crossref

Drug repurposing for non-small cell lung cancer by predicting drug response using pathway-level graph convolutional network

I T Anjusha iD, K A Abdul Nazeer iD, N Saleena iD

Journal of Bioinformatics and Computational Biology · 2025

DOI: 10.1142/s0219720025500015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bioinformatics and Computational Biology, 2025. Verfasst von I T Anjusha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science and Engineering, National Institute of Technology Calicut, Kozhikode, India. Hauptthemen laut MEDLINE: Drug Repositioning, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug repurposing is the process of identifying new clinical indications for an existing drug. Some of the recent studies utilized drug response prediction models to identify drugs that can be repurposed. By representing cell-line features as a pathway–pathway interaction network, we can better understand the connections between cellular processes and drug response mechanisms. Existing deep learning models for drug response prediction do not integrate known biological pathway–pathway interactions into the model. This paper presents a drug response prediction model that applies a graph convolution operation on a pathway–pathway interaction network to represent features of cancer cell-lines effectively. The model is used to identify potential drug repurposing candidates for Non-Small Cell Lung Cancer (NSCLC). Experiment results show that the inclusion of graph convolutional model applied on a pathway–pathway interaction network makes the proposed model more effective in predicting drug response than the state-of-the-art methods. Specifically, the model has shown better performance in terms of Root Mean Squared Error, Coefficient of Determination, and Pearson’s Correlation Coefficient when applied to the GDSC1000 dataset. Also, most of the drugs that the model predicted as top candidates for NSCLC treatment are either undergoing clinical studies or have some evidence in the PubMed literature database.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansComputational BiologyCell Line, TumorAlgorithms

Stichwörter der Autor:innen

Drug response predictionNSCLCdeep learningdrug repurposinggene expressiongraph convolutional networkgraph neural networkspathways

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Computer Science and Engineering, National Institute of Technology Calicut, Kozhikode, India.

ORCID-Profile: I T Anjusha, K A Abdul Nazeer, N Saleena

Zitieren

APA

Anjusha, I. T., Abdul Nazeer, K. A., & Saleena, N. (2025). Drug repurposing for non-small cell lung cancer by predicting drug response using pathway-level graph convolutional network. Journal of Bioinformatics and Computational Biology. https://doi.org/10.1142/s0219720025500015

Vancouver

Anjusha IT, Abdul Nazeer KA, Saleena N. Drug repurposing for non-small cell lung cancer by predicting drug response using pathway-level graph convolutional network. Journal of Bioinformatics and Computational Biology. 2025. doi:10.1142/s0219720025500015

BibTeX
@article{Anjusha2025,
  author = {Anjusha, I T and Abdul Nazeer, K A and Saleena, N},
  title = {Drug repurposing for non-small cell lung cancer by predicting drug response using pathway-level graph convolutional network},
  journal = {Journal of Bioinformatics and Computational Biology},
  year = {2025},
  doi = {10.1142/s0219720025500015}
}
Kostenlos starten →